Millions of Medicare beneficiaries who rely on prescription drugs will pay no more than $2,100 out of pocket for covered medications in 2026, a $100 increase from the $2,000 cap that took effect in 2025. The adjustment, confirmed by the Centers for Medicare & Medicaid Services, follows a statutory formula tied to rising drug spending rather than to wages or general inflation. For seniors living on fixed incomes, the gap between how fast the cap climbs and how fast their retirement checks grow could determine whether the protection keeps pace with their actual costs.
How the $2,100 cap changes Part D drug spending for seniors
Before 2025, Medicare Part D had no hard dollar limit on what enrollees could spend at the pharmacy counter. The Inflation Reduction Act created the first annual out-of-pocket ceiling, set at $2,000 for calendar year 2025. Once a beneficiary hits that threshold, catastrophic coverage kicks in and the enrollee owes nothing more for covered drugs for the rest of the year.
CMS first detailed the $2,000 ceiling and related benefit design changes in its 2025 rate guidance, which outlined how plan sponsors must structure Part D coverage as the new cap takes effect. That framework eliminated the five percent coinsurance that previously applied in the catastrophic phase and shifted more liability to plans and manufacturers once beneficiaries hit the limit.
The agency then confirmed in its 2026 rate announcement that the threshold rises to $2,100 for the coming plan year. That five-percent jump reflects the annual percentage increase, or API, a calculation written into the Social Security Act that tracks average per capita aggregate expenditures for covered Part D drugs. Because drug spending per person has historically grown faster than Social Security cost-of-living adjustments, the cap can outpace the income growth many retirees depend on.
The practical effect is straightforward but worth tracing year by year. A beneficiary who filled enough prescriptions to reach the $2,000 ceiling in 2025 would now need to spend $100 more before catastrophic coverage begins. For someone taking a single high-cost specialty medication, that difference may feel small. For enrollees juggling several brand-name drugs on tight budgets, each incremental increase chips away at the relief the cap was designed to provide.
The timing of expenses also matters. Many beneficiaries hit the limit early in the year because of a single hospitalization or a new diagnosis that requires expensive drugs. Others inch toward the cap month by month. For those on multiple chronic medications, premiums, deductibles and cost sharing all interact with the cap, and a higher threshold can mean more months of paying copays before costs fall to zero for the year.
Expenditure-based indexing versus fixed-income reality
The tension at the center of this policy sits in the indexing formula itself. Under Section 1860D-2 of the Social Security Act, CMS must adjust the out-of-pocket threshold each year using the API, which reflects aggregate Part D drug spending trends. If per capita drug expenditures rise by five percent, the cap rises by roughly five percent. If spending accelerates because of new high-cost therapies entering the market, the cap follows.
Typical Social Security benefit increases, by contrast, are pegged to the Consumer Price Index for Urban Wage Earners and Clerical Workers. Those adjustments have averaged less than the growth in prescription drug spending in many recent years. When drug-spending growth outstrips general consumer-price growth, the gap between a retiree’s income increase and the rising cap widens. Over a decade, compounding could push the threshold well above where it started in real purchasing-power terms for the average beneficiary.
CMS has not published the specific per-drug expenditure inputs it used to calculate the $100 increase from 2025 to 2026, and no beneficiary-level impact projections appear in the agency’s public fact sheets. That absence makes it difficult to estimate how many enrollees will hit the new threshold or how their experiences will differ from 2025. The agency has, however, signaled a broader interest in transparency around plan performance and utilization by soliciting feedback on Medicare Advantage and Part D data in a recent request for information.
For policymakers, the indexing question is not simply technical. If the cap climbs faster than seniors’ incomes, Congress could face pressure to revisit the formula or to add extra protections for low- and moderate-income beneficiaries. Options might include freezing the cap for a period, tying increases to a blended index that accounts for both drug costs and retiree incomes, or expanding subsidies that help eligible enrollees cover premiums and cost sharing.
For now, beneficiaries and advocates are focused on implementation details. Plan sponsors must update formularies, cost-sharing structures and member materials to reflect the $2,100 limit, and state health insurance counseling programs are preparing to explain the new rules during fall open enrollment. Seniors who routinely spend more than the cap on medications will still see substantial protection compared with pre-2025 law, but those whose costs hover near the threshold will feel the difference most acutely as the indexed cap edges upward year after year.
